Skip to content Skip to menu
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in UCL's privacy notices.

qMAP-PD - People recently diagnosed with Parkinson's

Who: People aged between 40 and 70 years who belong to one of the following groups:

  • People diagnosed with Parkinson’s within the last two years;
  • Healthy people who do not have a current diagnosis of Parkinson’s (or any other neurological condition);
  • People diagnosed with REM sleep Behavior Disorder (RBD).

Why: Disease course and presentation for Parkinson’s differ widely between individual patients. However, there is currently no reliable way to predict crucial clinical outcomes such as the rate of progression, response to medication and others. The qMAP-PD study aims to combine novel MRI anatomical imaging techniques with detailed clinical and genetic data to develop tools to predict clinical outcomes of interest for Parkinson’s patients.

What: Participants will be followed-up for assessments over four years. Assessments will include an advances MRI scan, completing of clinical scales and questionnaires evaluating Parkinsonian and other symptoms and cognitive abilities and a blood sample collection.

More information: qMAP-PD website.

Contact: Nicola Smith – Study Manager ()
Dr. Chris Lambert – principal investigator ()